Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc.

Kahn Swick & Foti is investigating Lantheus Holdings' proposed sale to Curium US Holdings. The deal offers Lantheus shareholders $102.50 per share in cash plus non-transferable contingent value rights worth up to an additional $12.00 per share, subject to potential future payments. The investigation introduces potential transaction-related legal scrutiny, though the article provides no allegation or outcome.

Analysis

The law-firm inquiry is not, by itself, a fundamental catalyst; these announcements are typically solicitation-driven and only become price-relevant if they produce a competing bid, injunction, or a material disclosure claim. The actionable variable is the merger-arbitrage spread versus the probability-weighted value of the CVR, not litigation headline flow. Investors should avoid assigning the CVR its headline maximum absent disclosed milestones, timing, and counterparty funding protections; non-transferability creates a meaningful liquidity discount even where the underlying asset outcome is favorable.

Near term, LNTH should trade as a deal-security rather than on diagnostic-imaging operating results. A narrow spread implies the market views antitrust and financing risk as low; a widening spread without deal-specific regulatory developments would be a more attractive entry than chasing legal-news volatility. The principal downside is a broken deal, where LNTH would revert to standalone valuation and face renewed scrutiny on Pylarify growth, reimbursement, and radiopharmaceutical competition from larger platforms including GE HealthCare (GEHC) and Siemens Healthineers (SHL.DE).

The non-obvious risk is regulatory overlap in nuclear medicine/radiopharmaceutical distribution rather than conventional pharma antitrust analysis. If regulators require asset divestitures or impose delays, the cash consideration may remain intact but annualized returns on the arb position deteriorate quickly. Over 6-18 months, a completed acquisition could strengthen Curium's scale in radiopharmaceutical manufacturing and distribution, potentially raising competitive pressure on independent imaging-agent suppliers; that is a strategic issue for LNTH's standalone downside case, not an immediate directional trade in GEHC.

Key Decisions for Investors

• Treat LNTH as a conditional merger-arbitrage watch: initiate only if the annualized gross spread to the $102.50 cash component exceeds approximately 12-15% after allowing a conservative $0-3 value for the CVR. Missing inputs before entry are current LNTH price, expected closing date, termination provisions, and regulatory filings.
• Do not buy LNTH solely on the shareholder-investigation release. Escalate only on an independently verifiable event: a revised bid, a formal regulatory second request, a definitive proxy disclosure, or litigation seeking to delay the shareholder vote.
• For an existing LNTH position, mark the CVR at a steep haircut until milestone definitions and payment timing are disclosed; risk-manage to cash consideration rather than headline total value. Reduce exposure if a regulatory review extends beyond the stated outside date or if the common-stock spread widens materially on deal-specific news.
• Use GEHC as a limited fundamental hedge/watch rather than a direct pair short: a failed transaction would leave LNTH competitively exposed, but GEHC's diversified earnings base makes it an imperfect offset. The thesis is falsified if LNTH demonstrates sustained post-deal-break operating guidance resilience or if Curium remedies eliminate meaningful competitive overlap.